CordenPharma Colorado Partners with BioMed Realty on Peptide Development Lab Expansion
Full-building, 15-year lease for 64,000 square feet enables CDMO CordenPharma Colorado to power next-generation peptide development in Boulder, Colorado.
Corden Pharma
CordenPharma Expands Peptide Manufacturing Platform in Switzerland
Contract development and manufacturing organization (CDMO) CordenPharma has finalized plans to establish a new peptide manufacturing facility in Switzerland located at Getec Park in Muttenz near Basel. This investment is part of the company’s growth initiatives with a more than €1 billion strategic investment in peptide development and manufacturing.
CordenPharma Invests €900 Million in Peptide Platform Expansion
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform.
CordenPharma & pHLIP Form RNA & Gene Delivery Alliance
CordenPharma and pHLIP have announced their strategic alliance to collaborate in developing and commercializing the pHLIP-LNP targeted delivery platform for RNA-based and genetic therapeutics.
CordenPharma Completes Upgrade of US Peptide Production Site in Colorado
CDMO CordenPharma, a specialist in active pharmaceutical ingredients (APIs), excipients, drug products and packaging services, inaugurated an increased commercial peptide production capacity with newly-upgraded facilities at its Colorado site in the US, which the company says is the world's largest solid-phase peptide synthesis (SPPS) manufacturing facility.
CordenPharma Expands at US Site in Colorado
CordenPharma is expanding strategically into synthetic oligonucleotide manufacturing at its plant at Boulder in the US state of Colorado. The two-phase investment is designed to provide innovative biotech and pharma customers with a fully integrated API to Drug Product service offering.
Wacker and CordenPharma in RNA Drugs Project
Together with Munich’s Ludwig Maximilian University (LMU) and the Humboldt University of Berlin (HU Berlin), German companies Wacker Chemie and CordenPharma International have launched a three-year project to accelerate the development of RNA-based drugs.
CordenPharma Lifts xRNA Capability in Italy
German CDMO CordenPharma, a specialist in Active Pharmaceutical Ingredients (APIs), excipients, drug products and packaging services (APIs), is investing more than €10 million in a new lipid nanoparticle (LNP) formulation, development and production area at its sterile injectable facility in Caponago, Italy.
CordenPharma Lifts Lipids Capacity in France
Full-service CDMO CordenPharma is making a major investment to increase lipid manufacturing capacity at its CordenPharma Chenôve facility near Dijon, France. The project is one of 25 based on mRNA technology that the French government is backing with altogether €585 million.
CordenPharma Sale Rumors Take Firm Shape
Rumors that German pharmaceutical producer CordenPharma is up for sale have resurfaced following fresh reports that the company’s owner, International Chemical Investors Group (ICIG), plans to formally solicit bids for the business at the end of January.
Wacker and CordenPharma in Lipid Nanoparticles Partnership
German chemical company Wacker and compatriot CDMO CordenPharma have agreed to jointly develop know-how and processes for manufacturing lipid nanoparticles (LNP) to meet growing market demand. Both companies will first build up R&D capacities at their respective sites – Wacker in Amsterdam, the Netherlands, and CordenPharma in Caponago, Italy.
CordenPharma Expands non-GMP Peptides
Reacting to recent growth in European domestic demand, Luxembourg-headquartered CordenPharma is expanding capacity for non-GMP peptides at its center of excellence for peptide process development and non-GMP manufacturing in Frankfurt, Germany.
Expert Interview: Michael Quirmbach, CordenPharma
So far, the pharmaceutical industry — including CMOs/CDMOs and CROs — has responded well to the outbreak of the Covid-19 pandemic. However, the coronavirus crisis has uncovered problems that have been smoldering beneath the surface and need to be addressed. That supply chains are vulnerable to disruption when major development, production and transportation hubs are blocked or shut down has become painfully obvious.
CordenPharma Expands US Peptide Capacity
CordenPharma has expanded peptide manufacturing capacity at its GMP API facility in Boulder, Colorado, USA, to accommodate what it said is “a large spike in demand” for peptide APIs and to continue its overall growth strategy.
Opportunities in Drug Development and Manufacturing
Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.
